Testing Tris-CAR-T cell therapy for newly diagnosed glioblastoma
Original title: Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a later stage trial, but it is still a test.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a new cell therapy, given along with standard treatment, for people just diagnosed with glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary.
Who this trial is for. This trial is for adults with newly diagnosed glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary who have had surgery. It tests Tris-CAR-T cells put into the brain, plus standard chemo and radiation.
Where it stands. The trial has not reported results. Plans call for 60 people, with 30 in each group. One group gets the cell therapy with standard care. The other group gets standard care alone. The team will track how long people go without the tumor growing, how long people live, and safety. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: This is one more idea being tested for a hard cancer. Someone who fits the trial could ask their care team about it. It is not care a doctor can give outside a study.
What it doesn't mean: A trial is a test, not a proven treatment. Joining one does not promise it will help you. It is not a promise of a cure. We cannot say who will be able to join.
Source: ClinicalTrials.gov, October 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.